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Background: B-Cell Activating Factor (BAFF) is a cytokine regulating antibody production. Polymorphisms in the
gene encoding BAFF were associated with the antibody response to Ascaris but not to mite allergens. In the
present study we evaluated the relationship between BAFF and specific antibodies against Ascaris and mites in 448
controls and 448 asthmatics. Soluble BAFF was measured by ELISA and BAFF mRNA by qPCR. Surface expression of
BAFF and its receptor (BAFF-R) was analyzed by flow cytometry.
Results: Individuals with specific IgE levels to Ascaris >75th percentile had lower levels of soluble BAFF; those with
specific IgG levels to Ascaris >75th percentile had reduced BAFF mRNA. Total IgE and specific IgE to mites were not
related to BAFF levels. There were no differences in soluble BAFF or mRNA levels between asthmatics and controls.
There was an inverse relationship between the cell-surface expression of BAFF-R on CD19+ B cells and BAFF levels
at the transcriptional and protein level.
Conclusions: These findings suggest that differences in BAFF levels are related to the strength of the antibody
response to Ascaris.
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Infection by Ascaris lumbricoides (ascariasis) is one of
the most prevalent helminthic diseases, affecting about
1.5 billion people worldwide. The immune response to this
nematode has as hallmarks the induction of anti-Ascaris
IgE/IgG antibodies and a strong Th2-driven inflammation
[1]. Specific antibodies to Ascaris have been associated to
parasite resistance [2-5] and both the immunoglobulin
repertoire as well as the strength of the antibody responses
are genetically regulated [6]. In mice, the production of
IgE to the Ascaris resistance marker ABA-1 is HLA re-
stricted [7]. In humans, two linkage scans identified a QTL
(Quantitative Trait Loci) on chromosome 13q33.3 associ-
ated with the susceptibility to A. lumbricoides [8,9]. This
region harbors the gene TNFSF13B (Tumor Necrosis Fac-
tor Ligand Superfamily, member 13b) encoding for the* Correspondence: lcaraballog@unicartagena.edu.co
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article, unless otherwise stated.cytokine B-Cell Activating Factor, BAFF. The wild type al-
lele of an intronic polymorphism in this gene (rs10508198)
was found associated with higher IgG levels against Ascaris
while the mutant allele was associated with less IgE to
ABA-1 in asthmatics patients [10] suggesting a role of
TNFSF13B in the antibody response to Ascaris.
BAFF (also known as BlyS, CD257), is a member of the
tumor necrosis factor ligand superfamily of cytokines and
is a major regulator of B cell activation, proliferation, dif-
ferentiation, survival and immunoglobulin class-switching
[11-13]. It is mainly expressed in innate immune cells such
as neutrophils, macrophages and dendritic cells [14,15]
but is also produced by non-hematopoietic cells [16,17].
This molecule may exist as cell surface-bound or soluble
forms, the latter secreted after a furin cleavage [18,19].
Soluble BAFF interacts with three receptors: TACI (trans-
membrane activator and calcium-modulating cyclophilin
ligand interactor), BCMA (B cell maturation antigen) and
BAFF-R (BAFF receptor or BR3), the latter expressed on
peripheral B cells [20,21]. In vitro experiments have dem-
onstrated the critical role of BAFF on the production oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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on the transcription of IgE [22]. In these processes the
BAFF-R also plays an important role [23,24].
Changes in BAFF levels are detectable in plasma during
different immune related conditions [16]. In addition, there
is evidence that upon nematode infection, resistant animals
have increased levels of BAFF. In cattle naturally exposed
to Ostertagia, Cooperia and Nematodirus the parasite-
resistant animals had increased BAFF mRNA levels in the
mesenteric lymph nodes [25]. High BAFF mRNA expres-
sion have been also detected in the spleen and liver of red
grouse infected with Trichostrongylus tenuis [26]. Further
studies in protozoan infections found that BAFF might be
associated to variations in the strength of specific anti-
bodies; for instance, administration of an antibody blocking
BAFF signaling in mice infected with Trypanosoma cruzi
induced a significant reduction of serum specific-IgM to
the parasite [27]. Besides, there is evidence that Plasmo-
dium parasites can modulate the BAFF pathway in the
host, compromising protective antibody memory [28]. Al-
though these investigations suggest that TNFSF13B may
be a candidate gene underlying phenotypic variation in re-
sponse to parasite infections, few have been done in
humans. There are no studies evaluating the role of BAFF
on the strength of Ascaris specific antibody production or
total IgE in humans naturally exposed to this parasite.
Since it has been observed that asthmatics have a higher
antibody response to nematodes [29], these individuals are
an interesting group for analyzing these traits. The aims of
this study were (a) to investigate the relationship betweenTable 1 Descriptive of the study population
Variables Asthmatic patients (n = 448
Age, years (Mean ± SD) 34.4 ± 18.2
Gender, female, n (%) 256 (57.1)
Soluble BAFF levels [pg/ml]a 768 (554.2–999.1)
mRNA levels BAFF1c (Mean ± SD) 3.21 ± 1.39
mRNA levels BAFF2c (Mean ± SD) 2.79 ± 1.04
Total IgE, UI/mla,e 699.7 (236.3–1065.8)
Ig levels to parasite (OD)a,e
sIgE to Ascaris 0.117 (0.100–0.150)
sIgG to Ascaris 1.99 (1.60–2.34)
sIgE to ABA-1 0.125 (0.098–0.187)
sIgG to ABA-1 1.49 (1.09–1.83)
Ig levels to HDM (OD)a,e
IgE to D. pteronyssinus 0.191 (0.115–0.520)
IgE to B. tropicalis 0.231 (0.110–1.06)
SD: Standard deviation.
aMedian (Inter Quartile Range).
bMann-Whitney U test.
cMeasured in PBMCs (n = 131, including 71 asthmatics and 60 controls).
dIndependent samples t-test.
eData available only for 369 asthmatics.BAFF and specific antibody levels to Ascaris, (b) to evalu-
ate the relationship between BAFF and total IgE and spe-
cific IgE to non-parasitic allergens in asthmatic patients
and non-asthmatic controls and (c) to evaluate the rela-
tionship between BAFF levels and the cell-surface expres-
sion of its receptor (BAFF-R) on CD19+ B cells.
Results and discussion
BAFF and the antibody response to Ascaris
The demographical characteristics and antibody responses
of the studied population are presented in Table 1. In the
entire dataset (n = 896), BAFF values in plasma were non-
normally distributed with median 792.1 pg/ml (interquar-
tile range 594.2–978.7 pg/ml) Figure 1A. There were no
differences in soluble BAFF levels according to age, gender
or disease status. IgE to Ascaris was higher in asthmatic
patients while IgG to Ascaris was higher in controls and
total serum IgE was higher in asthmatics (Table 1).
The relationship between levels of soluble BAFF and anti-
bodies to Ascaris was first evaluated using bivariate correla-
tions stratified by healthy and asthmatics. Because soluble
BAFF and the specific IgE levels to Ascaris were non-
normally distributed, the non-parametric Spearman test
was used. We found a significant inverse correlation be-
tween soluble BAFF and specific IgE to Ascaris (r = -0.10,
p = 0.03) in the group of healthy individuals (n = 448). A
similar tendency was observed when comparing soluble
BAFF levels between subjects with positive IgE sensitization
to Ascaris (OD ≥ 0.113, n = 392) and those non-sensitized
(n = 425): soluble BAFF was lower in Ascaris sensitized) Non-asthmatic controls (n = 448) p-value
36.7 ± 18.6 0.06
249 (55.6) 0.6
804.3 (628.5–964.3) 0.16b
3.12 ± 1.14 0.6d










Figure 1 BAFF levels according to the IgE antibody response to Ascaris. A. Distribution of soluble BAFF levels in the population; KS:
Kolmogorov-Smirnov B. Soluble BAFF levels in individuals with negative (n = 425) or positive (n = 392) IgE to Ascaris C. Distribution of specific IgE
to Ascaris; density (y-axis), optical density units (x-axis), shaded bars represent individuals with levels >75th percentile (upper panel). Soluble BAFF
levels between individuals with specific IgE levels to Ascaris below (n = 583) and above (n = 234) 75th percentile (lower panel). All lines indicate
geometric mean (95%CI), *p < 0.05.
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sensitized (829.6 pg/ml; IQR 653.3–1013, Mann-Whitney
U test, p = 0.03), Figure 1B.
Considering that parasite loads are over-dispersed within
populations [30] and that individuals at the extreme of the
distribution might carry biological traits influencing para-
site susceptibility, we analyzed the relationship between
soluble BAFF and the strength of the antibody response by
stratifying the participants according their antibody levels,
above 75th percentile (>75th) and below 75th percentile
(<75th), Figure 1C (upper panel). We found that those
with high specific IgE levels to the Ascaris extract (n =
234) had less concentrations of soluble BAFF in plasma
(median 786.3 pg/ml; IQR 573.8–985) than those with IgE
levels <75th percentile (n = 583, median 819.7 pg/ml; IQR
653.6–991.3; Mann-Whitney U test p = 0.04), Figure 1C.
This association remained significant in the linear regres-
sion model using the square-root transformed soluble
BAFF levels, and after adjustment by age, gender and dis-
ease status (p = 0.028). To explore if this relationship was
reflected at the gene expression level, we analyzed a sub-
group of subjects (n = 131) with mRNA data in peripheral
blood mononuclear cells (PBMCs), but we found no asso-
ciation between the relative expression of BAFF mRNA
and specific IgE levels to Ascaris (data not shown).Besides, there was no significant correlation between sol-
uble BAFF levels and IgG levels to Ascaris using non-
parametric tests. Since IgG levels were normally distributed,
we tested a more powerful parametric test (Pearson’s r)
using square-root-transformed soluble BAFF levels, with
similar results. Interestingly, there was a significant inverse
correlation between BAFF mRNA levels and IgG to
Ascaris (r = - 0.22, p = 0.01), Figure 2A. This relationship
was also observed when the comparison was done accord-
ing to the strength of the antibody response: individuals
with specific IgG levels to Ascaris >75th percentile had
lower BAFF1 mRNA levels (n = 40, mean 2.68 ± 1.0 SD)
than those < 75th percentile (n = 91, mean 3.38 ± 1.3 SD,
p = 0.003), Figure 2B.
The relationship between BAFF and serum antibody
levels has been extensively analyzed in the context of
autoimmune diseases, where increased levels of soluble
BAFF have been associated with increased titers of
auto-antibodies of the IgG isotype [11,31-34]. However,
the effects of BAFF on specific antibody levels may differ
depending on the context, for instance, inverse relation-
ships between BAFF mRNA levels and the risk of develop-
ing donor-specific antibodies have been observed after
transplantation [35]. To our knowledge this is the first
study suggesting a relationship between circulating BAFF
A B
Figure 2 BAFF mRNA levels according to the specific IgG to Ascaris. A. Correlation between the mRNA expression for BAFF1 and the levels
of specific IgG to Ascaris. The numbers indicate the Pearson correlation coefficient (r) and the p-value (two-tailed); each dot represents an
individual B. Distribution of specific IgG levels to Ascaris; density (y-axis), optical density units (x-axis), shaded bars represent individuals with IgG
levels >75th percentile (upper panel); BAFF1 mRNA levels between individuals with IgG to Ascaris below (n = 91) or above (n = 40) 75th percentile
(lower panel), **p < 0.005.
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In contrast to what is generally observed in auto-
immune diseases and some parasitic infections, we
found an inverse association between soluble BAFF and
the strength of the antibody response to Ascaris. The
fact that the same tendency was observed both at protein
and mRNA level is highly suggestive that it represents a
biological phenomenon. The mechanisms underlying this
relationship are unknown.
The mean difference in soluble BAFF levels between sub-
jects with high specific IgE to Ascaris and the rest of the
population was 52 pg/ml. The biological significance of this
finding need to be further investigated but there are several
studies suggesting that it could be relevant. It has been
shown that most of the systemic BAFF is bound to recep-
tors on B cell surfaces and that BAFF binding capacity on
follicular B cells is nearly saturated under steady-state con-
ditions in vivo [36]. In this scenery a small change in circu-
lating BAFF concentrations may affect the BAFF balance in
lymphoid tissues and impair the survival of high-affinity B
cells clones in the germinal center. In addition, it is known
that for some cytokines the biological impact is in the
order of few pg/ml; for example, concentrations of IFNγ
between healthy and malaria infected children differ in
8.1 pg/ml, and this small change correlated with sol-
uble BAFF levels and concentration of antibodies [37].Moreover, differences in cytokine levels upon stimulation
of PBMCs with phytohemagglutinin or Ascaris were small
but the impact on antibody production was remarkable
[38]. Differences in levels of pro-inflammatory cytokines
between healthy individuals and patients with autoimmune
conditions have been also described in this range [39].
Previous studies showed that TNFSF13B gene is a QTL
for Ascaris susceptibility [8,9], harboring genetic variants
associated with IgE response to Ascaris and worm burden
[10,40]. Now we have data suggesting that, in addition to
genetic evidence, there is a relationship between the anti-
body responses to Ascaris and BAFF at the protein and
mRNA level; although a causal relationship between them
has yet to be demonstrated. Our findings seem to be more
related to genetic mechanisms because first, there is pre-
vious evidence suggesting that polymorphisms around
TNFSF13B may influence the antibody responses and
second, we also found an association between the IgG re-
sponses and the level of mRNA expression. It is also per-
tinent to consider that A. lumbricoides can modify BAFF
levels during infection, as has been reported for malaria
parasite in acutely infected children [37]. However, in our
study it is not possible to assess a direct effect of the para-
site on BAFF production because it was designed to evalu-
ate the antibody responses to Ascaris and not the acute
infection. Besides, we should keep in mind that low BAFF
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consequences of the Ascaris infection without any causal
relationship. Indeed, IL-4 has shown to down-regulate the
expression of BAFF in vitro [41]. It is known that Ascaris
infections of low intensity are associated with a Th2 im-
mune response rich in IL-4 and in this population this
could be an additional factor introducing variability in
BAFF levels.
Soluble BAFF, total IgE, specific IgE and asthma
The relationship between BAFF and total plasma IgE is
still controversial [42-45]. In this study we found no asso-
ciation between soluble BAFF and total IgE when analyzed
as continuous variables. Total IgE values were transformed
to a categorical variable based on the 75th percentile in
non-asthmatic controls and asthmatic patients as a cut-off
to define high total IgE levels but there were no significant
differences (Figure 3). In addition, BAFF mRNA levels
were not associated with total IgE. Our findings are in
agreement with previous studies showing no relationship
between BAFF levels and total IgE [43]. Regarding specific
IgE to non-parasite/environmental allergens, we found
that BAFF levels were not related to specific IgE to D.
pteronyssinus and B. tropicalis, the main sensitizers in
this population. There are contradictory published results
around this point: it has been reported a significant in-
crease in BAFF levels after allergen exposure in the bron-
choalveolar lavage fluid of allergic patients [46] but no
relationship was found between soluble BAFF and specific
IgE reactivity to fungal allergens [42]. Our results support
previous findings detecting association between BAFF var-
iants and specific IgE to Ascaris but not to mites [10].
Some studies have suggested a relationship between BAFF
and asthma in humans [44,47]. However, in agreement
with Lei et al. [48], we found no differences in BAFFA Non-asthmatic controls
Figure 3 Soluble BAFF levels according to total IgE levels. A. Soluble B
(n = 335) or above (n = 113) 75th percentile B. Soluble BAFF levels in asthm
75th percentile.between asthmatic patients and controls neither at protein
nor at the mRNA levels (Table 1). It is worth mentioning
that our results refer to circulating form of the cytokine
and its expression in peripheral blood leukocytes. Al-
though several covariates might influence BAFF synthesis,
the levels we found in healthy controls were comparable
to those observed in other populations [49-51].
BAFF mRNA levels inversely correlate with the cell surface
expression of BAFF receptor (BAFF-R) on B cells
Since there were previous reports showing an inverse rela-
tionship between BAFF and BAFF receptor [50,52,53], the
expression of membrane-bound BAFF and BAFF-R was
evaluated on PBMCs (n = 113). We did not detect cell sur-
face expression of BAFF in gated CD14+ cells (monocytes),
lymphocytes or gated CD19+ cells (B cells); and, as previ-
ously described [54], the BAFF-R was highly expressed in
peripheral B cells but not in monocytes (Figure 4A). Simi-
lar findings were obtained when cell-surface expression of
BAFF and BAFF-R were analyzed in sorted monocytes
(Figure 4B) and B cells (Figure 4C) from six non-asthmatic
controls. As expected [54] we found that plasmablasts
(CD27high, CD38high), switched-memory B cells, mature
naïve B cells and transitional B cells expressed BAFF re-
ceptor (Additional file 1). The relationship between the
cell-surface expression of BAFF-receptor (BAFF-R) on
CD19+ B cells (median fluorescence intensity, MFI) with
the soluble BAFF levels and the BAFF mRNA levels in
PBMCs was evaluated in the subgroup of 113 individuals
with flow cytometry data. These observations had a nor-
mal distribution in this dataset and therefore parametric
tests (Pearson’s correlation) were used (Additional file 2).
We found a significant inverse correlation between BAFF1
mRNA and the cell surface expression of BAFF-R in CD19+
B cells (r = - 0.23, p = 0.01), Figure 5A. This finding wasFigure 3
B Asthmatic patients
AFF levels in non-asthmatic controls according to total IgE below
atics according to total IgE below (n = 277) or above (n = 92)
AB
C
Figure 4 Cell surface expression of BAFF and BAFF-R in PBMC, monocytes and B cells. A. Cell surface expression of BAFF and BAFF-R on
gated monocytes (CD14+) and B cells (CD19+). A representative example out of 113 PBMCs samples tested. IKO: isotype control B. Cell surface
expression of BAFF and BAFF-R in purified monocytes C. Cell surface expression of BAFF and BAFF-R in purified B cells.
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tion of monocytes in the sample as tested in a linear regres-
sion model. However, no correlation was found with
BAFF2 mRNA levels (r = - 0.13, p = 0.1). Regarding protein
levels, we found an inverse correlation between soluble
BAFF levels and the cell surface expression of BAFF-R in
CD19+ B cells (r = -0.27, p = 0.003) Figure 5B. These obser-
vations were significant after adjustment by age, gender, dis-
ease status and the proportion of monocytes in the sample.
The inverse relation between soluble BAFF levels and the
cell surface expression of BAFF-R has been previously re-
ported in mice and patients with deficiency of BAFF-R [50],
patients with systemic lupus erythematous and Sjogren’ssyndrome [52] hyper-IgE syndrome [53] and acute malaria
[37]. In this model, the 8.2% of the variance in BAFF-R ex-
pression can be explained by the soluble BAFF levels. In the
context of immune responses to Ascaris, it remains to be
elucidated how this BAFF/BAFF-R axis is related to the
synthesis of specific antibody levels.
The relationship between circulating soluble BAFF levels
and BAFF mRNA levels in blood mononuclear cells
Another question to be addressed was the relationship be-
tween soluble BAFF and BAFF mRNA levels, and whether
those can serve as proxies for mechanisms contributing to
the variation in specific antibody levels. Immune responses
A B
Figure 5 Relationship between cell surface expression of BAFF-R and BAFF levels. A. Correlation between the median fluorescence
intensity (MFI) of BAFF-R on gated CD19+ B cells and the mRNA levels for BAFF1 in PBMCs B. Correlation between the MFI of BAFF-R on gated
CD19+ B cells and soluble BAFF levels in plasma. The numbers indicate the Pearson correlation coefficient (r) and the p-value (two-tailed). Each
dot represents an individual.
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sues and in infiltrated organs. There, BAFF is produced by
many cells including lymphoid tissue stroma cells and resi-
dent monocytes [55,56]. Levels of circulating soluble BAFF
has shown to correlate with local BAFF activity at the ger-
minal center [36]. In this study we found a significant posi-
tive correlation (r = 0.68, p < 0.001), between the mRNA
levels for BAFF1 (exon 3-4) and BAFF2 (exon 4-6), how-
ever, soluble BAFF levels were only significantly correlated
to BAFF1 mRNA levels (Figure 6A) and not to BAFF2
mRNA (Figure 6B). From the transcripts to soluble BAFF
there are several steps: as a type II transmembrane protein
of 285 amino acids (aa) in the plasma membrane, BAFF is
cleaved by furine proteases in its N-terminal end (TNF-
homology domain) and released in the circulation. There
it forms homotrimers of 152 aa amenable to be detected
by ELISA; homotrimers can also form other assemblies of
less abundance (i.e. BAFF 60 mer) [16,57]. There is an-
other isoform expressed at low levels and called ΔBAFF
(266 aa), that can form heteromultimers with BAFF (285
aa) and negatively regulate the secretion of the latter [58].
The relation between soluble BAFF levels and BAFF1
mRNA levels could be explained because this transcriptA
Figure 6 The relationship between soluble BAFF levels and BAFF mRN
soluble BAFF levels and BAFF1 mRNA expression B. Correlation between so
the Pearson correlation coefficient (r) and the p-value (two-tailed). Each docontains exon 3, which is informative for both BAFF and
ΔBAFF. More studies are needed to elucidate if differential
expression of BAFF isoforms contribute to the strength of
specific antibody levels.
Conclusions
Our findings show that soluble BAFF levels are lower in
subjects with high specific IgE to Ascaris, suggesting that
this cytokine plays a role in the strength of the antibody
responses to this nematode and supporting previous mo-
lecular genetics studies. Interestingly, soluble BAFF levels
are not related with total IgE or IgE sensitization to house
dust mites, also in agreement with our previous findings.
In addition, we found no differences in BAFF levels be-
tween asthmatic patients and controls. As mRNA, BAFF
was expressed in mononuclear cells but, as a protein it
was not detected in cell-surface including monocytes and
B cells. The potential mechanistic link between lower
levels of BAFF and the strength of the specific antibodies
to Ascaris might be related with the inverse relationship
between BAFF levels and the BAFF-R expression on B
cells, a receptor that was present at the cell surface in
all developmental stages of peripheral B cells includingB
A levels in blood mononuclear cells. A. Correlation between
luble BAFF levels and BAFF2 mRNA expression. The numbers indicate
t represents an individual.
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the susceptibility to Ascaris infection and its clinical im-
plications deserve further confirmatory and mechanistic
studies in larger cohorts.
Methods
Study design and population
This is a case-control study performed in Cartagena,
Colombia. Eight hundred ninety six subjects including
448 asthmatics and 448 non-related healthy volunteers
were selected from a well-characterized dataset [10] and
matched by age and gender (Table 1). The matching
process was done randomly, without knowledge of anti-
Ascaris IgE or IgG levels. All participants live in an
urban, non-industrialized setting, having access to water
and electricity and belonging to the lower three (of six)
socio-economic strata in the city, where most people are
naturally exposed to A. lumbricoides. Measurements of
soluble BAFF (n = 896) were done in non-previously
thawed plasma samples from the repository in which
anti-Ascaris antibody determinations were done previ-
ously [10]. A random subgroup of these subjects (n =
131, 71 asthmatics and 60 controls) were visited by a
physician of the research staff who obtained 20 mL
blood samples for gene expression, flow cytometry ana-
lyses, soluble BAFF, total IgE and specific antibodies to
Ascaris and ABA-1. Asthma diagnosis was confirmed ac-
cording GINA guidelines, including spirometry. Allergic
sensitization was defined as a positive IgE result to the
mites Dermatophagoides pteronyssinus and/or Blomia
tropicalis. The study was approved by the Ethics Com-
mittee of the University of Cartagena. A full verbal ex-
planation of the investigation was given and written
informed consent was obtained from all participants.
Antibody measurements
Total IgE was determined by duplicate using an enzyme-
linked immunosorbent assay (ELISA) kit (RIDASCREEN;
R-Biopharm, Darmstadt, Germany) according to the man-
ufacturer’s instructions. Specific IgE and IgG to Ascaris ex-
tract and ABA-1 as well as specific IgE to mite extracts
were detected by ELISA as described previously [10,59].
ABA-1 is a nematode specific allergen from Ascaris (Asc s 1)
that is useful for avoiding cross reactivity with mite aller-
gens [59]. Also, antibody responses to ABA-1 have been as-
sociated with resistance to ascariasis [3,5]. The responses to
Ascaris and ABA-1 were analyzed as dichotomous vari-
ables, using two cut-off points: the first was the optical
density (OD) value of 0.113 (mean OD of six negative, non-
allergic, non-parasitized controls + 3 standard deviations)
which defined sensitized (positive) and non-sensitized
(negative) individuals. The second was the 75th percentile
of antibody levels in non-asthmatics individuals (i.e., 0.134
OD units for IgE to Ascaris; 0.154 OD units for IgE toABA-1; 2.68 OD units for IgG to Ascaris and 2.11 OD
units for IgG to ABA-1). To analyze the strength of total
IgE levels the 75th percentile was used as cut-off to define
high total IgE phenotype. This percentile was calculated
separately in healthy controls (>75th = 408.1 IU/mL) and
asthmatics (>75th = 1065.8 IU/mL).
Quantification of BAFF levels in plasma
Soluble BAFF in plasma was measured using a quantitative
sandwich enzyme immunoassay according to the manufac-
turer’s instructions (Quantikine Human BAFF/BLyS kit,
R&D Systems Cat. SBLYS0). A standard curve with four
parameter logistic (4-PL) curve-fit was used to extrapolate
the sample concentration value. Intra assay variation coef-
ficients were lower than 10%. The quantification range of
the assay was between 62.5 and 4000 pg/ml.
Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood was diluted 1:2 in 1× PBS and sepa-
rated by density gradient using Ficoll Histopaque
(Sigma Aldrich, Catalog 1077-1). Tubes were centri-
fuged during 30 minutes at 400 g at room temperature
and without brake. The layer containing the PBMCs
was transferred into a new tube, washed twice with 50
mL of 1× PBS and resuspended in 1 mL of 1× PBS. A
10μl aliquot was stained with 0.4% Trypan Blue and
counted in a hemocytometer. For gene expression ana-
lysis, 1 × 107 cells were placed in a new tube, centrifuged
at 300 g, 4°C during 5 minutes. The supernatant was
discarded and the cell pellet homogenized in 750 μl of
Trizol® (Life Technologies) and stored at -70°C until
use. The remaining cells were used for flow cytometry
analysis (see below).
RNA extraction
Cell homogenates were thawed during 15 minutes at
room temperature (protected from light) and 150 μl of
chloroform were added to each tube, vigorously mixed
by hand and centrifuged at 12 000 g during 15 minutes
at 4°C. The aqueous upper phase was transferred to a
fresh tube, diluted in 400 μl of 70% ethanol and pipetted
into a spin column (Trizol® Plus RNA purification kit,
Life Technologies, Catalog: 12183555). Each sample was
centrifuged at 12000 g during 15 seconds at room
temperature, the flow-through was discarded and the
column containing the RNA washed three times. The
spin column was centrifuged at 12 000 g during 1 mi-
nute and 50 μl of RNAse free water were added for
RNA elution (12 000 g during 2 minutes at room
temperature). The RNA yield was between 8.1 μg and
25 μg. The A260/A280 ratio ranged from 1.92 to 2.03
and for the ratio A260/A230 from 0.71 to 2.36. Integrity
of RNA was also verified by electrophoresis as two in-
tact bands of 28S and 18S ribosomal RNA.
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cDNA was synthesized from 1 μg of total RNA using the
Superscript III first strand super mix kit (Invitrogen, Cata-
log 11752050) following manufacturer’s instructions. RT-
PCR reactions included retrotranscriptase, reaction mix
(oligodT 22.5 μM, random hexamers 2.5 ng/μl, 10 mM
MgCl2 and dNTPs), total RNA and RNAse-free water
(Ambion Cat. AM9937). The synthesized cDNA was di-
luted with 80 μl of water and stored at -20°C until amplifi-
cation. cDNA was genomic-DNA free, confirmed by an
amplification reaction using a non retrotranscriptase en-
zyme control (RT-minus control).
Quantitative PCR
BAFF mRNA was detected by quantitative PCR (qPCR)
using Taqman gene expression assays on a 7300 Real-Time
Polymerase Chain Reaction (PCR) system (Applied Biosys-
tems, Foster City, CA, USA). To detect differential splicing,
the mRNA was measured in two separated assays: assay 1
targeting the exons 3 and 4 (Cat. Hs00198106, 84 bp ampli-
con) and assay 2 targeting the boundaries of exons 4–5 and
5–6 (Cat. Hs00902574, 73 bp amplicon). The two isoforms
were named BAFF1 and BAFF2 (Additional file 3). Expres-
sion of β2 micro-globulin was used as endogenous control
(Cat. Hs00984230, 81bp amplicon). Each sample was tested
by duplicate and the average CT value exported from the
SDS Software (Applied Biosystems). The CT value of the
β2M gene (Mean CT 18.8 ± 0.40 SD) was subtracted from
the CT values of the target genes (Mean CT 25.7 ± 0.60 SD
for BAFF1 and Mean CT 27.1 ± 0.67 SD for BAFF2). The
normalized value was expressed as the delta Ct (ΔCt =
CtBAFF – CtB2M). The highest ΔCT value among all samples
was subtracted from each sample and the resulting num-
ber expressed as the delta-delta CT. Relative expression
levels were calculated as 2^-(ΔΔCT) [60]. The probes for
BAFF were FAM-labeled and for β2 micro-globulin were
VIC-labeled, all assays included NFQ (non- fluorescent
quencher).
Flow cytometry on PBMCs
Cell surface expression of BAFF and BAFF-R was analyzed
on PBMCs by flow cytometry (n = 113). Cells were resus-
pended in MACS buffer (0.5% BSA in PBS) at a final con-
centration of 105 cells/100 μl per tube. Fcγ receptors were
blocked with 1 μl of normal mouse serum (e-Bioscience,
Catalog 24-5544) during 10 minutes at 4°C. A panel of
fluorochrome-conjugated monoclonal antibodies (APCe-
Fluor α-human CD14, Catalog: 47-0149; APC α-human
CD19, Catalog 17-0199; PE α-human BAFF/BLyS, Catalog
12-9017 and FITC α-human BR3/BAFF-R, Catalog 11-
9117, all from e-Bioscence) were added to the cells and in-
cubated 30 minutes at 4°C protected from light. Each
assay included the unstained sample and a panel of appro-
priate isotype controls to set the gates of positive andnegative populations. After staining, cells were washed
twice with PBS and resuspended in 500 μl of PBS. Data on
20000 events per sample were acquired using a Dako Cyto-
mation Cytometer (Beckman Coulter, Inc. CA, USA) and
analyzed by Summit 4.3 (Beckman Coulter, Inc. CA, USA).
Electronic gating was used to evaluate the expression of
BAFF and BAFF-R in CD14+ cells and CD19+ B cells.
Flow cytometry in purified monocytes and B cells
Peripheral blood monocytes and B cells were purified by
magnetic associated cell sorting (MACS) using negative
selection protocols (Monocyte Isolation kit catalog 130-
091-153 and B cells isolation kit catalog 130-091-151,
Miltenyi Biotec). Briefly, 30 × 106 PBMCs were resus-
pended in MACS buffer containing 0.5% BSA - PBS pH
7.2. Then, biotin-conjugated antibody cocktails were added
and the mixture incubated by 10 minutes at 4°C. Non
target cells were magnetically labeled with a cocktail of
monoclonal antibodies targeting CD2, CD14, CD16, CD36,
CD43 and CD235a for the B cell separation protocol and
CD3, CD7, CD16, CD19, CD56, CD123 and CD235a for
the monocyte separation protocol (Miltenyi Biotec). Anti-
biotin microbeads were added and the cells incubated by
15 minutes at 4°C. After washing, cells were resuspended
in MACS buffer at a final volume of 500 μl and passed
through the column. The flow-through was collected and
centrifuged at 300 g during 5 minutes at 4°C. The super-
natant was discarded, and the cells reconstituted in 500 μl
of MACS buffer and counted. Purified cells were stained
with specific antibodies to detect BAFF and BAFF-R in dif-
ferent subpopulations (Additional file 4). The purity of
monocytes and B cells was 91% and 90% respectively.
Statistics
Statistical analyses were performed using the statistical
package for the social sciences software (SPSS version 17
for Windows; SPSS Inc., Chicago, IL, USA) and GraphPad
Prism software v.5. Bivariate correlations were used to
analyze the relationship between soluble BAFF and the
antibody levels as continuous variables; since soluble BAFF
was non-normally distributed, the non-parametric Spear-
man test was used. IgG levels were normally distributed
therefore soluble BAFF levels were transformed to their
square root to achieve normality and the Pearson correl-
ation test was applied for this isotype. The comparisons of
soluble BAFF between the groups of antibody responders
(<75th and >75th) were done using Mann-Whitney U test
(p-values presented after 10000 permutations). Linear re-
gression was then used to model the effect of antibody
grouping on transformed soluble BAFF levels adjusting by
age, gender and disease status (asthma yes/no). Since
BAFF mRNA values in PBMCs were normally distributed
(Additional file 2), the comparison between groups of
antibody responders (<75th and >75th) were done by
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justed linear regression models. MFI of BAFF-R was
also normally distributed and its relationship with sol-
uble BAFF and transcript levels were explored using
Pearson correlation test. Since BAFF transcripts were
measured in unfractionated mononuclear cells, the per-
centage of monocytes per sample was included as covar-
iate in adjusted linear models. The relationship between
soluble BAFF levels and the mRNA levels of the tran-
scripts BAFF1 and BAFF2 was analyzed using Pearson
correlation test. A p value ≤0.05 (two-tailed) was con-
sidered statistically significant.
Additional files
Additional file 1: Cell surface expression of BAFF-R in subpopula-
tions of purified B cells.
Additional file 2: Distribution of the median intensity levels of
BAFF-R in B cells, soluble BAFF levels and mRNA levels in PBMCs for
the subgroup of 113 individuals.
Additional file 3: Schematic representation of the gene encoding
BAFF and the exons covered by the gene expression assays.
Additional file 4: Antibodies used for flow cytometry in PBMCs,
monocytes and B cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AB, NA performed experiments and statistical analyses; DM performed
antibody measurements; NA participated in the study design and supervised
data analysis. LC conceived the investigation and supervised the general
aspects of the work and data analyses. AB, NA, LC wrote the manuscript.
All authors read and approved the final version of the manuscript.
Acknowledgements
We thank all the patients and controls for their voluntary participation in the
study; also to our scientific collaborators at the Genetics and Molecular
Biology Group (University of Cartagena, Colombia) for the infrastructure
support to perform the cell isolations. We also thank Dr. Malcolm Kennedy
(University of Glasgow) for providing the ABA-1. This work was funded by
the Administrative Department of Science, Technology and Innovation
(Colciencias, Colombia) Grant 680-2009; and by the University of Cartagena,
Colombia. AB received funds from Fundemeb. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Received: 7 January 2014 Accepted: 2 June 2014
Published: 7 June 2014
References
1. Acevedo N, Caraballo L: IgE cross-reactivity between Ascaris lumbricoides
and mite allergens: possible influences on allergic sensitization and
asthma. Parasite Immunol 2011, 33(6):309–321.
2. Hagel I, Cabrera M, Buvat E, Gutierrez L, Santaella C, Borges R, Infante B,
Salas MC, Barrios Y: Antibody responses and resistance against Ascaris
lumbricoides infection among Venezuelan rural children: the influence
of ethnicity. J Trop Pediatr 2008, 54(5):354–356.
3. Turner JD, Faulkner H, Kamgno J, Kennedy MW, Behnke J, Boussinesq M,
Bradley JE: Allergen-specific IgE and IgG4 are markers of resistance and
susceptibility in a human intestinal nematode infection. Microbes Infect
2005, 7(7–8):990–996.
4. Hagel I, Lynch NR, Di Prisco MC, Rojas E, Perez M, Alvarez N: Ascaris
reinfection of slum children: relation with the IgE response. Clin Exp
Immunol 1993, 94(1):80–83.5. McSharry C, Xia Y, Holland CV, Kennedy MW: Natural immunity to Ascaris
lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen
and inflammation indicators in children. Infect Immun 1999, 67(2):484–489.
6. Dold C, Holland CV: Investigating the underlying mechanism of
resistance to Ascaris infection. Microbes Infect 2011, 13(7):624–631.
7. Kennedy MW, Tomlinson LA, Fraser EM, Christie JF: The specificity of the
antibody response to internal antigens of Ascaris: heterogeneity in
infected humans, and MHC (H-2) control of the repertoire in mice.
Clin Exp Immunol 1990, 80(2):219–224.
8. Williams-Blangero S, VandeBerg JL, Subedi J, Aivaliotis MJ, Rai DR,
Upadhayay RP, Jha B, Blangero J: Genes on chromosomes 1 and 13 have
significant effects on Ascaris infection. Proc Natl Acad Sci U S A 2002,
99(8):5533–5538.
9. Williams-Blangero S, Vandeberg JL, Subedi J, Jha B, Correa-Oliveira R,
Blangero J: Localization of multiple quantitative trait loci influencing
susceptibility to infection with Ascaris lumbricoides. J Infect Dis 2008,
197(1):66–71.
10. Acevedo N, Mercado D, Vergara C, Sanchez J, Kennedy MW, Jimenez S,
Fernandez AM, Gutierrez M, Puerta L, Caraballo L: Association between total
immunoglobulin E and antibody responses to naturally acquired Ascaris
lumbricoides infection and polymorphisms of immune system-related LIG4,
TNFSF13B and IRS2 genes. Clin Exp Immunol 2009, 157(2):282–290.
11. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R: The
level of BLyS (BAFF) correlates with the titre of autoantibodies in human
Sjogren’s syndrome. Ann Rheum Dis 2003, 62(2):168–171.
12. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson
JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL,
Mackay F, Mackay CR: B cell-activating factor belonging to the TNF family
(BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of
circulating T and B cells. J Immunol 2004, 173(2):807–817.
13. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F: The BAFF/
APRIL system: emerging functions beyond B cell biology and auto-
immunity. Cytokine Growth Factor Rev 2013, 24(3):203–215.
14. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella
MA: G-CSF-stimulated neutrophils are a prominent source of functional
BLyS. J Exp Med 2003, 197(3):297–302.
15. Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E, Tschopp J,
Schneider P, French LE: BAFF production by antigen-presenting cells
provides T cell co-stimulation. Int Immunol 2004, 16(3):467–475.
16. Mackay F, Schneider P: Cracking the BAFF code. Nat Rev Immunol 2009,
9(7):491–502.
17. Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J,
Wachsmann D: BAFF synthesis by rheumatoid synoviocytes is positively
controlled by alpha5beta1 integrin stimulation and is negatively
regulated by tumor necrosis factor alpha and Toll-like receptor ligands.
Arthritis Rheum 2007, 56(10):3202–3214.
18. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose
C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C,
Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor
necrosis factor family, stimulates B cell growth. J Exp Med 1999,
189(11):1747–1756.
19. Shapiro-Shelef M, Calame K: Regulation of plasma-cell development. Nat
Rev Immunol 2005, 5(3):230–242.
20. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C,
Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp
J, Browning JL, Ambrose C: BAFF-R, a newly identified TNF receptor that
specifically interacts with BAFF. Science 2001, 293(5537):2108–2111.
21. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG,
MacKay F, Bixler SA, Zafari M, Liu ZY, Woodcock SA, Qian F, Batten M, Madry
C, Richard Y, Benjamin CD, Browning JL, Tsapis A, Tschoop J, Ambrose C:
BAFF binds to the tumor necrosis factor receptor-like molecule B cell
maturation antigen and is important for maintaining the peripheral B
cell population. J Exp Med 2000, 192(1):129–135.
22. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A: DCs
induce CD40-independent immunoglobulin class switching through
BLyS and APRIL. Nat Immunol 2002, 3(9):822–829.
23. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H,
Geha RS: TACI and BAFF-R mediate isotype switching in B cells. J Exp Med
2005, 201(1):35–39.
24. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM,
Santini PA, Cerutti A: Epithelial cells trigger frontline immunoglobulin
Bornacelly et al. BMC Immunology 2014, 15:22 Page 11 of 11
http://www.biomedcentral.com/1471-2172/15/22class switching through a pathway regulated by the inhibitor SLPI.
Nat Immunol 2007, 8(3):294–303.
25. Araujo RN, Padilha T, Zarlenga D, Sonstegard T, Connor EE, Van Tassel C,
Lima WS, Nascimento E, Gasbarre LC: Use of a candidate gene array to
delineate gene expression patterns in cattle selected for resistance or
susceptibility to intestinal nematodes. Vet Parasitol 2009, 162(1–2):106–115.
26. Webster LM, Mello LV, Mougeot F, Martinez-Padilla J, Paterson S, Piertney
SB: Identification of genes responding to nematode infection in red
grouse. Mol Ecol Resour 2011, 11(2):305–313.
27. Bermejo DA, Amezcua-Vesely MC, Montes CL, Merino MC, Gehrau RC, Cejas
H, Acosta-Rodriguez EV, Gruppi A: BAFF mediates splenic B cell response
and antibody production in experimental Chagas disease. PLoS Negl Trop
Dis 2010, 4(5):e679.
28. Scholzen A, Sauerwein RW: How malaria modulates memory: activation
and dysregulation of B cells in Plasmodium infection. Trends Parasitol
2013, 29(5):252–262.
29. Acevedo N, Erler A, Briza P, Puccio F, Ferreira F, Caraballo L: Allergenicity of
Ascaris lumbricoides tropomyosin and IgE sensitization among
asthmatic patients in a tropical environment. Int Arch Allergy Immunol
2011, 154(3):195–206.
30. Dold C, Holland CV: Ascaris and ascariasis. Microbes Infect 2011, 13(7):632–637.
31. Lopez De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS,
Ytterberg SR, Amin S, Peterson EJ, Baechler EC, Reed AM: BAFF expression
correlates with idiopathic inflammatory myopathy disease activity
measures and autoantibodies. J Rheumatol 2013, 40(3):294–302.
32. Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte
stimulator levels in patients with systemic immune-based rheumatic
diseases. Arthritis Rheum 2001, 44(6):1313–1319.
33. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P:
BAFF overexpression is associated with autoantibody production in
autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34–39.
34. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D,
Morelli A, Ferraccioli G: Concentrations of BAFF correlate with
autoantibody levels, clinical disease activity, and response to treatment
in early rheumatoid arthritis. J Rheumatol 2008, 35(7):1256–1264.
35. Thibault-Espitia A, Foucher Y, Danger R, Migone T, Pallier A, Castagnet S,
G-Gueguen C, Devys A, C-Gautier A, Giral M, Soulillou JP, Brouard S: BAFF
and BAFF-R levels are associated with risk of long-term kidney graft
dysfunction and development of donor-specific antibodies. Am J
Transplant 2012, 12(10):2754–2762.
36. Goenka R, Matthews AH, Zhang B, O’Neill PJ, Scholz JL, Migone TS, Leonard
WJ, Stohl W, Hershberg U, Cancro MP: Local BLyS production by T
follicular cells mediates retention of high affinity B cells during affinity
maturation. J Exp Med 2014, 211(1):45–56.
37. Nduati E, Gwela A, Karanja H, Mugyenyi C, Langhorne J, Marsh K, Urban BC:
The plasma concentration of the B cell activating factor is increased in
children with acute malaria. J Infect Dis 2011, 204(6):962–970.
38. Geiger SM, Massara CL, Bethony J, Soboslay PT, Carvalho OS, Correa-Oliveira R:
Cellular responses and cytokine profiles in Ascaris lumbricoides and Trichuris
trichiura infected patients. Parasite Immunol 2002, 24(11–12):499–509.
39. Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ,
Todd I: Systemic cytokine levels and the effects of etanercept in TNF
receptor-associated periodic syndrome (TRAPS) involving a C33Y
mutation in TNFRSF1A. Rheumatology 2006, 45(1):31–37.
40. Williams-Blangero S, Fenstad MH, Kumar S, Blangero J: Genetics of Human
Host Susceptibility to Ascariasis. In Ascaris: The Neglected Parasite. Edited
by Holland C. London: Elsevier; 2013:315–340.
41. Zhou L, Zhong R, Hao W, Wang H, Fan X, Zhang L, Mi Q: Interleukin-10
and interferon-gamma up-regulate the expression of B-cell activating
factor in cultured human promyelocytic leukemia cells. Exp Mol Pathol
2009, 87(1):54–58.
42. Chen Y, Lind Enoksson S, Johansson C, Karlsson MA, Lundeberg L, Nilsson G,
Scheynius A, Karlsson MC: The expression of BAFF, APRIL and TWEAK is
altered in eczema skin but not in the circulation of atopic and
seborrheic eczema patients. PLoS One 2011, 6(7):e22202.
43. Lied GA, Lillestol K, Valeur J, Berstad A: Intestinal B cell-activating factor: an
indicator of non-IgE-mediated hypersensitivity reactions to food? Aliment
Pharmacol Ther 2010, 32(1):66–73.
44. Kang JS, Yoon YD, Ahn JH, Kim SC, Kim KH, Kim HM, Moon EY: B cell-
activating factor is a novel diagnosis parameter for asthma. Int Arch
Allergy Immunol 2006, 141(2):181–188.45. Jee HM, Kim KW, Hong JY, Sohn MH, Kim KE: Increased serum B cell-
activating factor level in children with atopic dermatitis. Clin Exp
Dermatol 2010, 35(6):593–598.
46. Kato A, Xiao H, Chustz RT, Liu MC, Schleimer RP: Local release of B cell-
activating factor of the TNF family after segmental allergen challenge of
allergic subjects. J Allergy Clin Immunol 2009, 123(2):369–375.
47. Jee HM, Choi BS, Kim KW, Sohn MH, Han MY, Kim KE: Increased B cell-
activating factor (BAFF) level in the sputum of children with asthma.
Korean J Pediatr 2010, 53(8):795–800.
48. Lei Z, Liu G, Huang Q, Lv M, Zu R, Zhang GM, Feng ZH, Huang B: SCF and
IL-31 rather than IL-17 and BAFF are potential indicators in patients with
allergic asthma. Allergy 2008, 63(3):327–332.
49. Migita K, Abiru S, Maeda Y, Nakamura M, Komori A, Ito M, Fujiwara S, Yano
K, Yatsuhashi H, Eguchi K, Ishibashi H: Elevated serum BAFF levels in
patients with autoimmune hepatitis. Hum Immunol 2007, 68(7):586–591.
50. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A,
Lougaris V, Quinti I, Thon V, Litzman J, Schlesier M, Warnatz K, Thiel J, Rolink
AG, Eibel H: Soluble BAFF levels inversely correlate with peripheral B cell
numbers and the expression of BAFF receptors. J Immunol 2012,
188(1):497–503.
51. Matharu K, Zarember KA, Marciano BE, Kuhns DB, Spalding C, Garofalo M,
Dimaggio T, Estwick T, Huang CY, Fink D, Priel DL, Fleisher TA, Holland SM,
Malech HL, Gallin JI: B-cell activating factor (BAFF) is elevated in chronic
granulomatous disease. Clin Immunol 2013, 148(2):258–264.
52. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C,
Gestermann N, Proust A, Lambotte O, Mariette X: Decreased B cell
activating factor receptor expression on peripheral lymphocytes
associated with increased disease activity in primary Sjogren’s syndrome
and systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):790–797.
53. Meyer-Bahlburg A, Renner ED, Rylaarsdam S, Reichenbach J, Schimke LF,
Marks A, Tcheurekdjian H, Hostoffer R, Brahmandam A, Torgerson TR,
Belohradsky BH, Rawlings DJ, Ochs HD: Heterozygous signal transducer
and activator of transcription 3 mutations in hyper-IgE syndrome result
in altered B-cell maturation. J Allergy Clin Immunol 2012, 129(2):559–562.
562 e551–552.
54. Schneider P: The role of APRIL and BAFF in lymphocyte activation. Curr
Opin Immunol 2005, 17(3):282–289.
55. Tertilt C, Joh J, Krause A, Chou P, Schneeweiss K, Crystal RG, Worgall S: Expression
of B-cell activating factor enhances protective immunity of a vaccine against
Pseudomonas aeruginosa. Infect Immun 2009, 77(7):3044–3055.
56. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML: Normal B
cell homeostasis requires B cell activation factor production by
radiation-resistant cells. J Exp Med 2003, 198(6):937–945.
57. Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, Ingold K, Tardivel A,
Krushinskie D, Eldredge J, Silvian L, Lugovskoy A, Farrington GK, Strauch K,
Schneider P, Whitty A: Formation of virus-like clusters is an intrinsic property
of the tumor necrosis factor family member BAFF (B cell activating factor).
Biochemistry 2006, 45(7):2006–2013.
58. Gavin AL, Ait-Azzouzene D, Ware CF, Nemazee D: DeltaBAFF, an alternate
splice isoform that regulates receptor binding and biopresentation of
the B cell survival cytokine, BAFF. J Biol Chem 2003, 278(40):38220–38228.
59. Acevedo N, Sanchez J, Erler A, Mercado D, Briza P, Kennedy M, Fernandez A,
Gutierrez M, Chua KY, Cheong N, Jiménez S, Puerta L, Caraballo L: IgE cross-
reactivity between Ascaris and domestic mite allergens: the role of
tropomyosin and the nematode polyprotein ABA-1. Allergy 2009,
64(11):1635–1643.
60. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25(4):402–408.
doi:10.1186/1471-2172-15-22
Cite this article as: Bornacelly et al.: The strength of the antibody
response to the nematode Ascaris lumbricoides inversely correlates with
levels of B-Cell Activating Factor (BAFF). BMC Immunology 2014 15:22.
